Nanobiomaterials' applications in neurodegenerative diseases

Area of Science:

• Neuroscience
• Biotechnology
• Materials Science

Background:

• The blood-brain barrier (BBB) protects the central nervous system but hinders drug delivery.
• High systemic drug doses are often needed for brain penetration, causing adverse effects.
• Effective drug delivery to the brain is crucial for treating neurological disorders.

Purpose of the Study:

• To review nanotechnology-based strategies for treating neurodegenerative diseases.
• To explore the potential of nanostructures in enhancing drug delivery across the BBB.
• To discuss the current status of nanotechnology in Alzheimer's, Parkinson's, and ALS treatment.

Main Methods:

• Review of existing literature on nanotechnology and drug delivery for neurodegenerative diseases.
• Discussion of nanomaterial properties, biocompatibility, and cell-material interactions.
• Analysis of nanotechnology-based therapeutic approaches for Alzheimer's, Parkinson's, and ALS.

Main Results:

• Nanotechnology provides tools (1-100 nm nanostructures) to overcome BBB limitations.
• Drug release systems are the most frequently reported nanotechnology strategy for brain drug delivery.
• Various nanomaterials show promise for treating Alzheimer's, Parkinson's, and ALS.

Conclusions:

• Nanotechnology-based drug delivery systems are a promising strategy for treating neurodegenerative diseases.
• Further research into nanomaterial interactions and optimized drug release is essential.
• Nanotechnology holds significant potential to improve therapeutic outcomes for brain disorders.